Global Gene Editing Technologies Market Report 2023: Sector is Expected to Reach $16.37 Billion by 2032 at a CAGR of 27.5%


Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Gene Editing Technologies Market - A Global and Regional Analysis: Focus on Offering, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032" report has been added to's offering.

The global gene editing technologies market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032.

The growth in the global gene editing technologies market is expected to be driven by an increase in the need for personalized medicine. In addition, the introduction of new technologies fuelled the growth of gene editing technologies.

Market Lifecycle Stage

The global gene editing technologies market is in progressing phase. The creation, production, and distribution of tools and services for gene editing are under the purview of the gene editing technology market. Utilizing ways to change DNA sequences, gene editing technologies can be used to treat genetic illnesses, create disease-resistant crops, and generate study models for animals.

The market for gene editing technology is made up of numerous businesses that sell CRISPR-Cas9, TALENs, and zinc finger nucleases, among other types of gene editing tools. Researchers, pharmaceutical corporations, and biotech companies employ these techniques to create novel treatments, vaccines, and diagnostic devices.

Moreover, manufacturers began to produce application-specific gene editing technologies in recent years.


Clustered regularly interspaced short palindromic repeats Cas9 (CRISPR-Cas9) and other gene editing technologies have the potential to revolutionize the healthcare sector and have a big impact on the world economy. Treatments for genetic problems and diseases such as cancer, HIV, and cystic fibrosis may become more accurate and successful because of gene editing technology.

This might result in lower healthcare expenses and better patient outcomes. New intellectual property rights could be established because of the advancement of gene editing technologies, which would lead to a sharp rise in the number of patent applications.

Recent Developments in the Global Gene Editing Technologies Market

  • In March 2023, Seamless Therapeutics launched with $12.5 million seed financing to advance a transformative gene editing platform based on programmable precision designer recombinases.
  • In June 2022, Precision BioSciences, Inc. entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG to develop a custom ARCUS nuclease that would be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta-thalassemia.
  • In November 2021, Cytovia Therapeutics, Inc. and Cellectis S.A. expanded their TALEN gene-edited iNK partnership to enable broader collaboration in China.
  • In February 2022, Integrated DNA Technologies, Inc. (IDT), a provider of global genomics solutions, introduced Alt-R HDR Donor Blocks to support researchers in advancing scientific breakthroughs in gene editing. This enhanced solution was designed to improve homology-directed repair (HDR) rates in large fragment knock-in experiments.
  • In March 2023, Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application for NTLA-2002. This was an in vivo investigational therapy based on CRISPR, intended for the treatment of Hereditary Angioedema (HAE).
  • In April 2022, Thermo Fisher Scientific Inc.'s latest Gibco CTS TrueCut Cas9 Protein, manufactured under Good Manufacturing Practices (GMP), facilitates genome editing for both research and manufacturing purposes, including research on CAR T-cell therapy.
  • In November 2022, Ionis Pharmaceuticals, Inc. and Metagenomi announced a collaboration that may bring together Ionis' extensive knowledge in RNA-targeted therapeutics with Metagenomi's versatile next-generation gene editing systems. The aim of this collaboration was to pursue both established and new genetic targets that may offer the potential for expanding treatment options for patients.

Demand - Drivers and Limitations

The following are the demand drivers for the global gene editing technologies market:

  • Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
  • Increasing Investments and Funding Opportunities in Gene Editing Space
  • Increased Demand for Personalized Medicines

The market is expected to face some limitations due to the following challenges:

  • Limited Expertise and Facilities for Gene Editing Technologies
  • Ethical Considerations and Their Consequences Regarding Human Gene Editing

Key Companies Profiled

  • Addgene
  • BRAIN Biotech AG
  • Cellectis S.A.
  • Creative Biolabs
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • DNA Script
  • GeneCopoeia, Inc.
  • Magento, Inc.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PerkinElmer Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Key Attributes:

Report AttributeDetails
No. of Pages240
Forecast Period2023 - 2032
Estimated Market Value (USD) in 2023$1.84 Billion
Forecasted Market Value (USD) by 2032$16.37 Billion
Compound Annual Growth Rate27.5%
Regions CoveredGlobal

Key Topics Covered:

1 Product Definition

2 Market Scope

3 Research Methodology

4 Market Overview
4.1 Market Overview
4.2 Market Footprint and Potential Growth Scenario
4.2.1 Realistic Growth Scenario
4.2.2 Optimistic Growth Scenario
4.2.3 Pessimistic Growth Scenario
4.3 Evolution of Gene Editing Technologies
4.4 Clinical Trials

5 Industry Outlook
5.1 Regulatory Landscape
5.1.1 Legal Requirements and Frameworks in the U.S. Clinical Trial Authorization Marketing Authorization USFDA Guidelines for BLA Submission Post-Authorization Regulations
5.1.2 Legal Requirements and Frameworks in Europe EMA Biologics License Application Process Centralized Procedure Decentralized Procedure Mutual-Recognition Procedure National Procedure
5.1.3 Legal Requirements and Frameworks in Asia-Pacific Legal Requirements and Framework in Japan
5.1.4 Expedited Regulatory Designations Around the World
5.2 Product Benchmarking
5.2.1 Product Benchmarking (by Technology)
5.2.2 Comparative Analysis
5.3 Technology Adoption Matrix
5.4 Industry Trends
5.4.1 Leveraging Collaboration as a Major Key Strategies to Create Opportunities for Gene Editing Technologies
5.4.2 Growing Focus on Gene Therapies
5.5 Patent Analysis
5.5.1 Patent Analysis (by Year)
5.5.2 Patent Analysis (by Technology)
5.5.3 Patent Analysis (by Region)
5.5.4 Patent Analysis (by Country)

6 Global Gene Editing Technologies Market: Market Dynamics
6.1 Business Drivers
6.1.1 Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
6.1.2 Increasing Investments and Funding Opportunities in Gene Editing Space
6.1.3 Increased Demand for Personalized Medicines
6.1.4 Impact Analysis
6.2 Business Restraints
6.2.1 Limited Expertise and Facilities for Gene Editing Technologies
6.2.2 Ethical Considerations and Their Consequences Regarding Human Gene Editing
6.2.3 Impact Analysis
6.3 Business Opportunities
6.3.1 Increasing Numbers of Clinical Trials Utilizing Gene Editing Technologies for the Treatment of Genetic Diseases
6.3.2 Growing Applications of Gene Editing Technologies in Agri-Food Tech

7 Global Gene Editing Technologies Market: Competitive Insights
7.1 Key Developments and Strategies
7.1.1 Funding Activities
7.1.2 New Offerings
7.1.3 Mergers and Acquisitions
7.1.4 Partnerships, Alliances, and Business Expansions
7.1.5 Regulatory and Legal Activities
7.2 Key Development Analysis
7.3 Company Share Analysis

8 Global Gene Editing Technologies Market (by Offering), Value ($Million), 2022-2032
8.1 Overview
8.2 Gene Editing Products
8.2.1 Kits and Enzymes CRISPR Vector-Based Cas9 DNA-Free Cas9 Non-CRISPR
8.2.2 Antibodies
8.2.3 Libraries
8.2.4 Accessories
8.3 Gene Editing Services

9 Global Gene Editing Technologies Market (by Technology), Value ($Million), 2022-2032
9.1 Overview
9.2 CRISPR Gene Editing Technology
9.3 Non-CRISPR Gene Editing Technology
9.3.1 Zinc-Finger Nucleases (ZFNs)
9.3.2 TAL Effector Nucleases (TALENs)
9.3.3 Meganucleases

10 Global Gene Editing Technologies Market (by Application), Value ($Million), 2022-2032
10.1 Overview
10.2 Agricultural
10.3 Biomedical
10.3.1 Drug Discovery
10.3.2 Gene Therapy
10.3.3 Diagnostics

11 Global Gene Editing Technologies Market (by End User), Value ($Million), 2022-2032
11.1 Overview
11.2 Academic Institutes and Research Centers
11.3 Life Sciences Companies
11.4 Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)

12 Global Gene Editing Technologies Market (by Region), Value ($Million), 2022-2032

13 Company Profiles

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Gene Editing Technologies Market